chr21-43066243-C-T
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 15P and 1B. PM1PP2PP3_StrongPP5_Very_StrongBS2_Supporting
The NM_000071.3(CBS):c.451G>A(p.Gly151Arg) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000178 in 1,349,764 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. 14/24 in silico tools predict a damaging outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G151V) has been classified as Uncertain significance.
Frequency
Consequence
NM_000071.3 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- classic homocystinuriaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), Myriad Women’s Health, PanelApp Australia, ClinGen, Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000346 AC: 4AN: 115474Hom.: 1 Cov.: 16 show subpopulations
GnomAD2 exomes AF: 0.0000121 AC: 3AN: 248820 AF XY: 0.00000741 show subpopulations
GnomAD4 exome AF: 0.0000162 AC: 20AN: 1234290Hom.: 3 Cov.: 27 AF XY: 0.0000130 AC XY: 8AN XY: 616944 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000346 AC: 4AN: 115474Hom.: 1 Cov.: 16 AF XY: 0.0000532 AC XY: 3AN XY: 56404 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Classic homocystinuria Pathogenic:2
- -
- -
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
The c.451G>A variant (also known as p.G151R), located in coding exon 3 of the CBS gene, results from a G to A substitution at nucleotide position 451. This change occurs in the last base pair of coding exon 3, which makes it likely to have some effect on normal mRNA splicing. In addition to potential splicing impact, this alteration changes the glycine at codon 151 to arginine, an amino acid with dissimilar properties. This variant has been observed in multiple individuals with homocystinuria, some of whom were homozygous or compound heterozygous with another CBS alteration (Kraus JP et al. Hum. Mutat., 1999;13:362-75; Linnebank M et al. Hum. Mutat., 2004 Oct;24:352-3; Katsushima F et al. Mol. Genet. Metab., 2006 Apr;87:323-8; Poloni S et al. Mol Genet Genomic Med, 2018 03;6:160-170). An in vitro assay involving yeast plasmids showed that cells with this alteration required glutathione supplementation to support growth, indicating severe loss of function (Mayfield JA et al. Genetics, 2012 Apr;190:1309-23). Both the nucleotide position and amino acid positions are highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to weaken the efficiency of the native splice donor site; however, direct evidence is unavailable. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
not provided Pathogenic:1
In vitro functional assays demonstrated loss of CBS enzyme activity (Mayfield et al., 2012; Katsushima et al., 2006); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25087612, 25525159, 29352562, 22267502, 15365998, 16307898, 10338090) -
HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED Pathogenic:1
This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 151 of the CBS protein (p.Gly151Arg). This variant also falls at the last nucleotide of exon 5, which is part of the consensus splice site for this exon. This variant is present in population databases (rs373782713, gnomAD 0.008%). This missense change has been observed in individuals with homocystinuria (PMID: 10338090, 15365998, 16307898, 29352562). ClinVar contains an entry for this variant (Variation ID: 863694). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CBS function (PMID: 16307898, 20066033, 22267502). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). For these reasons, this variant has been classified as Pathogenic. -
CBS-related disorder Pathogenic:1
The CBS c.451G>A variant is predicted to result in the amino acid substitution p.Gly151Arg. This variant was reported in the homozygous and compound heterozygous states in individuals with homocystinuria (Kraus et al. 1999. PubMed ID: 10338090; Katsushima et al. 2006. PubMed ID: 16307898; Poloni et al. 2018. PubMed ID: 29352562). Functional studies showed that this variant results in impaired enzyme activity and altered assembly of the CBS tetramer (Katsushima et al. 2006. PubMed ID: 16307898; Mayfield et al. 2012. PubMed ID: 22267502). This variant is reported in 0.0081% of alleles in individuals of African descent in gnomAD. This variant is interpreted as pathogenic. -
Homocystinuria Pathogenic:1
Variant summary: CBS c.451G>A (p.Gly151Arg) results in a non-conservative amino acid change located in the Pyridoxal-phosphate dependent enzyme domain (IPR001926) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. This variant is located in an exonic splicing region. Several computational tools predict a significant impact on normal splicing: Four predict that the variant abolishes or weakens a canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 1.2e-05 in 248820 control chromosomes. c.451G>A has been reported in the literature in multiple individuals affected with Homocystinuria (e.g. Kraus_1999, Linnebank_2004, Katsushima_2006, Poloni_2018). These data indicate that the variant is very likely to be associated with disease. Several publications report experimental evidence indicating that the variant results in severely reduced enzyme activity in-vitro when studied in E. coli or yeast models (e.g. Katsushima_2006, Singh_2010, Mayfield_2012). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, citing the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at